Medical Developments International Ltd
ASX:MVP

Watchlist Manager
Medical Developments International Ltd Logo
Medical Developments International Ltd
ASX:MVP
Watchlist
Price: 0.52 AUD Market Closed
Market Cap: 58.6m AUD

Relative Value

The Relative Value of one MVP stock under the Base Case scenario is 1.15 AUD. Compared to the current market price of 0.52 AUD, Medical Developments International Ltd is Undervalued by 55%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MVP Relative Value
Base Case
1.15 AUD
Undervaluation 55%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
82
vs Industry
57
Median 3Y
2
Median 5Y
2.9
Industry
2.6
Forward
1.3
vs History
11
vs Industry
Median 3Y
-2.5
Median 5Y
-9.8
Industry
21.6
Forward
-28.6
vs History
vs Industry
Median 3Y
-5.1
Median 5Y
-8.9
Industry
16.5
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-7.2
Industry
22.5
vs History
65
vs Industry
57
Median 3Y
1
Median 5Y
1.4
Industry
2.3
vs History
82
vs Industry
66
Median 3Y
1.5
Median 5Y
2.1
Industry
2.9
Forward
0.9
vs History
82
vs Industry
74
Median 3Y
2.1
Median 5Y
2.8
Industry
5.5
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-6.2
Industry
13
Forward
-105
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-6.2
Industry
16.6
Forward
18.3
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-6.6
Industry
15.8
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-6.1
Industry
19.1
vs History
65
vs Industry
54
Median 3Y
1
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

MVP Competitors Multiples
Medical Developments International Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Medical Developments International Ltd
ASX:MVP
58.6m AUD 1.5 623.2 -24.1 -24.1
US
Eli Lilly and Co
NYSE:LLY
993.4B USD 16.7 54 36.2 38.8
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
508.5B USD 5.5 20.2 16.5 21.5
CH
Roche Holding AG
SIX:ROG
256.1B CHF 4.2 27.2 11.6 13.6
UK
AstraZeneca PLC
LSE:AZN
209.1B GBP 4.8 29.8 108.1 158.3
CH
Novartis AG
SIX:NOVN
206.4B CHF 4.6 18 11.4 14.8
US
Merck & Co Inc
NYSE:MRK
243.7B USD 3.8 12.8 9.1 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.5 9.5 11
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
142.5B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
AU
Medical Developments International Ltd
ASX:MVP
Average P/E: 90.3
623.2
137%
4.5
US
Eli Lilly and Co
NYSE:LLY
54
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.2
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.2
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
US
Merck & Co Inc
NYSE:MRK
12.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Medical Developments International Ltd
ASX:MVP
Average EV/EBITDA: 438.7
Negative Multiple: -24.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.2
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.5
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.6
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.1
10%
10.8
CH
Novartis AG
SIX:NOVN
11.4
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
2%
4.7
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Medical Developments International Ltd
ASX:MVP
Average EV/EBIT: 1 881.1
Negative Multiple: -24.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.6
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3